TOP 100 MAGAZINE

Guillem Singla Buxarrais

​​

With a deep-rooted passion for improving patient outcomes through innovation, Guillem Singla Buxarrais is leading a revolution in neuro-rehabilitation. As co-founder and CEO of Neurofenix, he has built the company into a national leader in virtual therapy for neurological conditions, enabling patients to recover mobility and independence from the comfort of home.

 

Backed by 15 years of experience in neurotechnology and biomedical engineering, Guillem oversees company strategy, clinical innovation, business development, and long-term growth. He has forged partnerships with more than 40 leading health systems and rehab providers across the U.S., secured Medicare and MA reimbursement, and successfully raised over $12 million in funding and grants. Under his leadership, Neurofenix has successfully completed 4 clinical trials and delivered over 680,000 therapy sessions to more than 3,000 patients—an impact that earned the company a spot among the Top 50 MedTech Startups transforming U.S. healthcare.

 

A former researcher at the Brain and Behaviour Lab at Imperial College London and the Institute of Bioengineering of Catalonia, Guillem worked alongside world-renowned scientists in AI and mechanobiology. He holds an MSc in neurotechnology from Imperial College and a BSc in biomedical engineering from the University of Barcelona. His contributions earned him recognition as one of the UK’s Most Innovative Engineers by the Royal Academy of Engineering.

 

Serving patients across the U.S. and the UK, Neurofenix combines AI, telehealth, gamification, and sensor-based medical device technology to deliver evidence-based, at-home neuro-rehab covered by insurance—bringing therapy to those who need it most.

​

 

Guillem Singla Buxarrais
Co-Founder and CEO
Neurofenix
Website: www.neurofenix.com

LinkedIn: www.linkedin.com/in/guillemsingla